We are live on ! Find out more
TARS icon

Tarsus Pharmaceuticals
TARS

116 hedge funds and large institutions have $692M invested in Tarsus Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 48 increasing their positions, 22 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

552% more call options, than puts

Call options by funds: $2.99M | Put options by funds: $458K

118% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 22

65% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 17

31% more capital invested

Capital invested by funds: $529M → $692M (+$162M)

11.77% more ownership

Funds ownership: 91.33% → 103.11% (+12%)

10% more funds holding

Funds holding: 105 → 116 (+11)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

Holders
116
Holders Change
+11
Holders Change %
+10.48%
% of All Funds
1.69%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
28
Increased
48
Reduced
22
Closed
17
Calls
$2.99M
Puts
$458K
Net Calls
+$2.53M
Net Calls Change
+$2.26M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$64.1M
2
PBA
Paradigm Biocapital Advisors
New York
+$17.1M
3
BlackRock
BlackRock
New York
+$5.11M
4
RI
RTW Investments
New York
+$4.54M
5
NCM
Nantahala Capital Management
Connecticut
+$4M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$13.4M
2
Millennium Management
Millennium Management
New York
-$10.2M
3
VC
Vivo Capital
California
-$7.98M
4
CAM
Cormorant Asset Management
Massachusetts
-$6.68M
5
SCM
Soleus Capital Management
Connecticut
-$4.44M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$4.81M +$2.29M +137,377 +137%
N
27
Nuveen
North Carolina
$4.79M +$2.18M +130,841 +124%
ECM
28
ExodusPoint Capital Management
New York
$4.72M -$2.77M -165,741 -42%
Charles Schwab
29
Charles Schwab
California
$4.43M +$505K +30,268 +16%
Millennium Management
30
Millennium Management
New York
$4.02M -$10.2M -609,707 -75%
Allspring Global Investments
31
Allspring Global Investments
North Carolina
$3.8M -$978K -58,558 -24%
SSA
32
Schonfeld Strategic Advisors
New York
$3.64M -$1.08M -64,641 -26%
Norges Bank
33
Norges Bank
Norway
$3.24M +$2.67M +160,100 New
Macquarie Group
34
Macquarie Group
Australia
$3.04M – – –
BFM
35
Boothbay Fund Management
New York
$2.26M – – –
IHAM
36
Integral Health Asset Management
New York
$2.02M +$1.67M +100,000 New
Invesco
37
Invesco
Georgia
$1.98M +$1.63M +97,873 New
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$1.85M +$1.53M +91,423 New
Connor, Clark & Lunn Investment Management (CC&L)
39
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.82M +$825K +49,382 +121%
EAM
40
Exome Asset Management
New York
$1.71M +$1.41M +84,400 New
Bank of New York Mellon
41
Bank of New York Mellon
New York
$1.66M +$179K +10,745 +15%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
42
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$1.5M +$1.24M +74,000 New
JGC
43
J. Goldman & Co
New York
$1.46M -$894K -53,565 -43%
Aberdeen Group
44
Aberdeen Group
United Kingdom
$1.46M +$1.2M +72,032 New
Two Sigma Investments
45
Two Sigma Investments
New York
$1.46M +$298K +17,842 +33%
GWA
46
GGM Wealth Advisors
Maryland
$1.38M – – –
Two Sigma Advisers
47
Two Sigma Advisers
New York
$1.34M +$86.8K +5,200 +9%
SG Americas Securities
48
SG Americas Securities
New York
$1.11M +$71.2K +4,266 +8%
Ameriprise
49
Ameriprise
Minnesota
$1.08M +$2.42K +145 +0.3%
Barclays
50
Barclays
United Kingdom
$957K +$595K +35,622 +306%
1
2
3 4 5

TARS Hedge Fund Activity: Q4 2023 in Review

116 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q4 2023, worth a combined $692M — up 31% from $529M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new TARS positions and 17 closed out — a net gain of 11 holders — while 48 added to existing stakes and 22 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $64.1M. The largest seller was Deerfield Management, exiting entirely with an estimated $13.4M sold.

  • 116 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q4 2023, up from 105 in Q3 2023.
  • Funds reported $692M of Tarsus Pharmaceuticals stock for Q4 2023, up 31% quarter-over-quarter.
  • 28 funds opened new Tarsus Pharmaceuticals positions in Q4 2023 and 17 closed out, a net change of +11 holders.
  • The largest Tarsus Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $64.1M added.
  • The largest Tarsus Pharmaceuticals seller in Q4 2023 was Deerfield Management, an estimated $13.4M sold.

Based on aggregated 13F filings for Q4 2023.